Clinical trials: Hypertriglyceridaemia
Severe Hypertriglyceridemia
Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL
To determine the efficacy of MAT9001 compared to placebo in lowering fasting triglyceride levels in subjects with very high fasting triglyceride levels ≥ 500 and < 2000 mg/dL.
- Trial name
- AMPLIFY (NCT04662528)
- Testing
- MAT9001 (omega-3 pentaenoic acid)
- Sponsor
- Matinas Biopharma, Inc
Hypertriglyceridemia
Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides
The purpose is to investigate the effect of oral doses of SLx-4090 over 14 days on subjects with high triglycerides.
- Trial name
- NCT00562575
- Testing
- SLx-4090
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Response Pharmaceuticals
LDL Cholesterol, Triglycerides
Safety and Efficacy of a Natural Health Product in Reducing Cholesterol and Triglyceride Levels.
The purpose of this study is to assess the safety and efficacy of a natural health product among participants with elevated LDL cholesterol and triglyceride levels.
- Trial name
- NCT01028274
- Testing
- Investigational Product 1, Investigational Product 2
- Where
- Canada
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Nordic Pharma, USA
Hypertriglyceridemia, Mixed Hyperlipidemia
A Pilot Study to Evaluate the Lipid Effects of TRIA-662
The purpose of this pilot study is to learn what study factors are important in designing a large, full-scale study of the effects of TRIA-662 on serum triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) levels.
- Trial name
- NCT02008084
- Testing
- TRIA-662
- Where
- 17 sites in Canada
- Volunteers
- 71 people
- Sponsor
- Cortria Corporation
Hypertriglyceridemia
Efficacy of TAK-085 in Participants With Hypertriglyceridemia
The purpose of this study was to determine the efficacy and safety of TAK-085, once daily (QD) or twice daily (BID), compared to ethyl eicosapentaenoate (EPA-E), three times daily (TID) in participants with hypertriglyceridemia…
- Trial name
- NCT01350973
- Testing
- Omega-3-acid ethyl esters 90 (TAK-085), Eicosapentaenoic acid-ethyl (EPA-E)
- Volunteers
- 611 people
- Sponsor
- Takeda
Severe Hypertriglyceridemia
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat…
- Trial name
- ECLIPSE (NCT01208961)
- Testing
- Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypertriglyceridemia
An Efficacy and Safety Study of Omacor® in Taiwanese Hypertriglyceridemic Patients
1. Evaluation of the efficacy of Omacor® in Taiwanese hypertriglyceridemia patients 2. Evaluation of the safety of Omacor® in Taiwanese hypertriglyceridemia patients
- Trial name
- NCT01725646
- Testing
- Omacor®
- Where
- 4 sites in Taiwan
- Volunteers
- 253 people
- Sponsor
- Excelsior
Severe Hypertriglyceridemia
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.
- Trial name
- NCT05681351
- Testing
- Olezarsen
- Where
- 262 sites in United States, Argentina and 31 more
- Volunteers
- 885 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2, Hypertriglyceridemia
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
The design of the Phase 2 clinical trial includes the following elements: Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs.
- Conditions
- Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT05464784
- Testing
- MN-001
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- MediciNova
Hypertriglyceridemia
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 26 weeks in participants with Hypertriglyceridemia.
- Trial name
- NCT02300233
- Testing
- Volanesorsen
- Where
- 45 sites in United States, Canada and 4 more
- Volunteers
- 114 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypertriglyceridemia
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
This study is intended to evaluate the potential 2-way reciprocal interaction between multiple doses of Epanova™ and a single dose of rosuvastatin
- Trial name
- ECLIPSEIII (NCT02859129)
- Testing
- rosuvastatin 40 mg tablet, Epanova™ QD (2 x 1 g capsules), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Severe Hypertriglyceridemia
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.
- Trial name
- ENTRUST (NCT05852431)
- Testing
- Pegozafermin
- Where
- 177 sites in United States, Argentina and 18 more
- Volunteers
- 369 people
- Sponsor
- 89bio, Inc.
Non-alcoholic Steatohepatitis, Hypertriglyceridemia
Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
This is a multi-center, proof-of-principle, open-label study designed to evaluate the efficacy, safety, and tolerability of MN-001 in non-alcoholic steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) subjects…
- Conditions
- Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease, Hypercholesterolemia
- Trial name
- NCT02681055
- Testing
- MN-001
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- MediciNova
Hypertriglyceridemia
Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy
The purpose of this study is to determine if implitapide is effective in lowering triglyceride (TG) levels in patients with Fredrickson Type I or V hypertriglyceridemia where the maximum tolerable medication and diet were not…
- Trial name
- NCT00080132
- Testing
- implitapide
- Where
- 9 sites in United States, Netherlands and 1 more
- Volunteers
- 50 people
- Sponsor
- Medical Research Laboratories International
Lipoprotein Lipase Deficiency, Familial, Hyperlipoproteinemia Type I
Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia
The purpose of this study is to assess safety and efficacy of CAT-2003 in patients with chylomicronemia. The study will evaluate the effects of CAT-2003 on fasting total and chylomicron triglyceride levels, as well as…
- Conditions
- Lipoprotein Lipase Deficiency, Familial, Hyperlipoproteinemia Type I, Chylomicronemia, Familial, Hypertriglyceridemia
- Trial name
- NCT02098278
- Testing
- CAT-2003
- Where
- 2 sites in Canada
- Volunteers
- 13 people
- Sponsor
- Catabasis Pharmaceuticals
Hypercholesterolemia, Hypertriglyceridemia
Efficacy and Safety of Gemcabene in Patients With Low HDL-C and Either Normal or Elevated Triglycerides
The purpose of this study is to evaluate the effect of gemcabene on HDL-C, LDL-C, TG, and other lipid levels in patients with low HDL-C
- Trial name
- NCT02585869
- Testing
- Gemcabene 150 mg, Gemcabene 300 mg, Gemcabene 600 mg
- Volunteers
- 161 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Dyslipidaemias
Dyslipidemia Study Investigating The Increase In "Good Cholesterol"
An eight week comparison of the investigational drug GW590735, placebo, and the marketed drug fenofibrate intended to increase the levels of "good cholesterol" and decrease levels of "bad cholesterol" in healthy patients with low…
- Trial name
- NCT00169559
- Testing
- GW590735, fenofibrate
- Where
- 50 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Hypertriglyceridemia
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
The primary objective of this study is to determine the effect of Epanova® on the pharmacokinetic and anticoagulant activity of warfarin.
- Trial name
- NCT01431690
- Testing
- warfarin, omefas, omega-3-acid ethyl esters
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
sHTG, HTG With ASCVD (Diagnosed or at Increased Risk)
A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.
This is a multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial evaluating the efficacy and safety of FXR0906 in patients with severe hypertriglyceridemia or hypertriglyceridemia with atherosclerotic…
- Trial name
- NCT07889245
- Testing
- FXR0906 injection
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.
Severe Hypertriglyceridemia
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.
- Trial name
- SHASTA-2 (NCT04720534)
- Testing
- ARO-APOC3
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 229 people
- Sponsor
- Arrowhead Pharmaceuticals